Ace-inhibitor (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 218 | Alport syndrome | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00309257 (ClinicalTrials.gov) | January 2004 | 30/3/2006 | Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome | Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome | Alport Syndrome | Drug: ACE I, ATA II and Statins;Drug: Benazepril, Valsartan and Fluvastatin | Mario Negri Institute for Pharmacological Research | NULL | Completed | 15 Years | 70 Years | Both | 9 | Phase 2 | Italy |
| 2 | NCT02378805 (ClinicalTrials.gov) | July 1995 | 26/2/2015 | European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome | European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies | Alport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease;Thin Basement Membrane Disease;Familial Benign Hematuria | Drug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: Paricalcitol | University Hospital Goettingen | Society for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive Medicine | Recruiting | N/A | N/A | All | 500 | Germany |